Chinook Therapeutics EBIT

Chinook Therapeutics (KDNY) currently reports a EBIT of $-250M as of June 2023. That compares with $-76M in the prior-year period — down 228.5% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Chinook Therapeutics's EBIT history and peer comparisons.

Chinook Therapeutics's EBIT decreased from $-76M to $-250M — a 228.5% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Chinook Therapeutics's EBIT of $-250M is lower than the Healthcare sector average of $110B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Chinook Therapeutics reported $-250M in EBIT as of June 2023. That compares with $-76M in the prior-year period — down 228.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-250M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Chinook Therapeutics, and consider following KDNY for alerts when major investors trade the stock.